유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

novartis europharm limited - erenumab - choroby migreny - Środki przeciwbólowe - aimovig wskazany jest w profilaktyce migreny u dorosłych, którzy mają co najmniej 4 dni migreny w miesiącu po rozpoczęciu leczenia z aimovig.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - zwyrodnienie plamki żółtej - okulistyka - beovu jest wskazany u dorosłych w leczeniu wysiękowej postaci (na mokro) związane z wiekiem zwyrodnienie plamki żółtej (amd).

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - preparaty do obturacyjne choroby dróg oddechowych, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - preparaty do obturacyjne choroby dróg oddechowych, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - preparaty do obturacyjne choroby dróg oddechowych, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - stwardnienie rozsiane, Рецидивно-znika - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

novartis europharm limited - trawoprost - ocular hypertension; glaucoma, open-angle - ophthalmologicals, antiglaucoma preparations and miotics - zmniejszenie podwyższonego ciśnienia wewnątrzgałkowego u dorosłych pacjentów z nadciśnieniem ocznym lub jaskrą z otwartym kątem przesączania (patrz punkt 5). obniżenie podwyższonego ciśnienia wewnątrzgałkowego w pediatrycznych pacjentów w wieku 3 lat, < 18 lat na nadciśnienie oczne lub jaskry dziecięcej.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

novartis europharm limited - ruksolitynib (w postaci fosforanu) - myeloproliferative disorders; polycythemia vera; graft vs host disease - Środki przeciwnowotworowe - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. policitemia wiara (pv)jakavi jest wskazany do leczenia dorosłych pacjentów z policitemia wiara, które są odporne na lub nietolerancja гидроксимочевины. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - obrazowanie radionuklidami - diagnostyczne radiofarmaceutyki - ten produkt leczniczy jest przeznaczony wyłącznie do celów diagnostycznych. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.